 MONMOUTH JUNCTION, N.J., Aug. 11, 2021 GLOBE NEWSWIRE -- Advaxis, Inc. Nasdaq: ADXS Advaxis or the Company, a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products, announced that it has received a letter indicating that following the Companys hearing before the Nasdaq Hearings Panel the Panel, the Panel determined to grant the Company an extension through November 22, 2021, to comply with Nasdaqs 1.00 Minimum Bid Price Rule and complete its previously announced merger transaction with Biosight, Ltd. Biosight. On July 6, 2021, Advaxis announced that it had entered into a merger agreement with Biosight, a privately held, Israel-based pharmaceutical company developing innovative therapeutics for hematological malignancies and disorders. 